163 related articles for article (PubMed ID: 10229636)
1. delta Opioid affinity and selectivity of 4-hydroxy-3-methoxyindolomorphinan analogues related to naltrindole.
Coop A; Rothman RB; Dersch C; Partilla J; Porreca F; Davis P; Jacobson AE; Rice KC
J Med Chem; 1999 May; 42(9):1673-9. PubMed ID: 10229636
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
3. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
4. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
[TBL] [Abstract][Full Text] [Related]
5. 14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors.
Kshirsagar TA; Fang X; Portoghese PS
J Med Chem; 1998 Jul; 41(14):2657-60. PubMed ID: 9651172
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors.
Gao P; Larson DL; Portoghese PS
J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, opioid receptor binding, and functional activity of 5'-substituted 17-cyclopropylmethylpyrido[2',3':6,7]morphinans.
Ananthan S; Kezar HS; Saini SK; Khare NK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem Lett; 2003 Feb; 13(3):529-32. PubMed ID: 12565965
[TBL] [Abstract][Full Text] [Related]
8. 7-Arylidenenaltrexones as selective delta1 opioid receptor antagonists.
Ohkawa S; Portoghese PS
J Med Chem; 1998 Oct; 41(21):4177-80. PubMed ID: 9767654
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and delta-opioid receptor antagonist activity of a naltrindole analogue with a regioisomeric indole moiety.
Portoghese PS; Ohkawa S; Moe ST; Takemori AE
J Med Chem; 1994 Jun; 37(12):1886-8. PubMed ID: 8021929
[TBL] [Abstract][Full Text] [Related]
10. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
11. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
[TBL] [Abstract][Full Text] [Related]
12. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
13. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
[TBL] [Abstract][Full Text] [Related]
14. The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors.
Rogers H; Hayes AG; Birch PJ; Traynor JR; Lawrence AJ
J Pharm Pharmacol; 1990 May; 42(5):358-9. PubMed ID: 1976787
[TBL] [Abstract][Full Text] [Related]
15. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
[TBL] [Abstract][Full Text] [Related]
16. Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.
Schiller PW; Berezowska I; Nguyen TM; Schmidt R; Lemieux C; Chung NN; Falcone-Hindley ML; Yao W; Liu J; Iwama S; Smith AB; Hirschmann R
J Med Chem; 2000 Feb; 43(4):551-9. PubMed ID: 10691681
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro investigation of naltrindole, a delta-opioid antagonist.
Ayres EA; Davis P; Burks TF
Proc West Pharmacol Soc; 1990; 33():55-63. PubMed ID: 2177196
[No Abstract] [Full Text] [Related]
18. 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.
Ohkawa S; DiGiacomo B; Larson DL; Takemori AE; Portoghese PS
J Med Chem; 1997 May; 40(11):1720-5. PubMed ID: 9171881
[TBL] [Abstract][Full Text] [Related]
19. The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole.
Black SL; Jales AR; Brandt W; Lewis JW; Husbands SM
J Med Chem; 2003 Jan; 46(2):314-7. PubMed ID: 12519069
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of naltrexone-derived delta-opioid antagonists. Role of conformation of the delta address moiety.
Portoghese PS; Sultana M; Moe ST; Takemori AE
J Med Chem; 1994 Mar; 37(5):579-85. PubMed ID: 8126697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
